A dermatologist guide to immunogenicity()()

Dermatologists should be aware that autoantibody formation may occur after the initiation of biologic therapy. This phenomenon has been referred to as immunogenicity and biologic fatigue. Because of this, patients may experience loss of clinical efficacy to a particular drug. To combat this phenomen...

Descripción completa

Detalles Bibliográficos
Autores principales: Blattner, Collin M., Chaudhari, Soham P., Young, John, Murase, Jenny E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5418886/
https://www.ncbi.nlm.nih.gov/pubmed/28492015
http://dx.doi.org/10.1016/j.ijwd.2016.05.001
_version_ 1783234137671335936
author Blattner, Collin M.
Chaudhari, Soham P.
Young, John
Murase, Jenny E.
author_facet Blattner, Collin M.
Chaudhari, Soham P.
Young, John
Murase, Jenny E.
author_sort Blattner, Collin M.
collection PubMed
description Dermatologists should be aware that autoantibody formation may occur after the initiation of biologic therapy. This phenomenon has been referred to as immunogenicity and biologic fatigue. Because of this, patients may experience loss of clinical efficacy to a particular drug. To combat this phenomenon, low-dose immunomodulators may be used in hopes of preventing autoantibodies. We review the current literature and provide a basic treatment algorithm for patients with moderate to severe psoriasis.
format Online
Article
Text
id pubmed-5418886
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-54188862017-05-10 A dermatologist guide to immunogenicity()() Blattner, Collin M. Chaudhari, Soham P. Young, John Murase, Jenny E. Int J Womens Dermatol Article Dermatologists should be aware that autoantibody formation may occur after the initiation of biologic therapy. This phenomenon has been referred to as immunogenicity and biologic fatigue. Because of this, patients may experience loss of clinical efficacy to a particular drug. To combat this phenomenon, low-dose immunomodulators may be used in hopes of preventing autoantibodies. We review the current literature and provide a basic treatment algorithm for patients with moderate to severe psoriasis. Elsevier 2016-07-18 /pmc/articles/PMC5418886/ /pubmed/28492015 http://dx.doi.org/10.1016/j.ijwd.2016.05.001 Text en © 2016 The Authors http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Blattner, Collin M.
Chaudhari, Soham P.
Young, John
Murase, Jenny E.
A dermatologist guide to immunogenicity()()
title A dermatologist guide to immunogenicity()()
title_full A dermatologist guide to immunogenicity()()
title_fullStr A dermatologist guide to immunogenicity()()
title_full_unstemmed A dermatologist guide to immunogenicity()()
title_short A dermatologist guide to immunogenicity()()
title_sort dermatologist guide to immunogenicity()()
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5418886/
https://www.ncbi.nlm.nih.gov/pubmed/28492015
http://dx.doi.org/10.1016/j.ijwd.2016.05.001
work_keys_str_mv AT blattnercollinm adermatologistguidetoimmunogenicity
AT chaudharisohamp adermatologistguidetoimmunogenicity
AT youngjohn adermatologistguidetoimmunogenicity
AT murasejennye adermatologistguidetoimmunogenicity
AT blattnercollinm dermatologistguidetoimmunogenicity
AT chaudharisohamp dermatologistguidetoimmunogenicity
AT youngjohn dermatologistguidetoimmunogenicity
AT murasejennye dermatologistguidetoimmunogenicity

Ejemplares similares